A one-pot s nthesis of no-carrier added y-amin0[4-~~C]butyric acid (GABA) starting with h drogen [zC]cyanide prepared from [llC]carbon dioxide, is presented. Hydrogen [&]cyanide was trapped in tetrahydrofuradpotassium hydroxide in the presence of the amino polyether Kryptofix 2.2.2. A Michael additi
Synthesis of 4-amino [4-11C]butyric acid (GABA)
✍ Scribed by G. Antoni; P. Malmborg; B. Langström
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- French
- Weight
- 91 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0022-2135
No coin nor oath required. For personal study only.
✦ Synopsis
The so called fast transmitters either excicatory such as glutamate and aspartate or the inhibitory neuro-transmitter 4-aminobutyric acid (GABA) are involved in a multitude of important regulatory processes in the brain.(l) It may be possible to study some of these processes using [11C]GABA in combination with other tracers and PET. GABA has earlier been labelled with 13N using an enzymatic reaction.(2) We have now developed a one-pot synthesis of no carrier added [4-11C]GABA starting with hydrogen [IlC] cyanide.
📜 SIMILAR VOLUMES
The synthesis of the title compound is described. It involves base catalyzed substitution of deuterium for hydrogen in 3-p- -chlorophenylglutaric acid which is subsequently transformed to baclofen. The overall yield is 80%. ## INTRODUCTION AND DISCUSSION In order to develop a mass fragmentographi
## Abstract Ring‐opening of __N__‐(__tert__‐butoxycarbonyl)aziridine‐2‐isopropyl carboxylate with no‐carrier‐added (n.c.a.) [^11^C]cyanide is reported. Following purification by HPLC, the protected D,L‐[4‐^11^C]__β__‐cyanoalanine was subsequently hydrolysed, to yield D,L‐[4‐^11^C]asparagine or D,L‐
## Abstract The crystal structure of 4‐amino‐3‐(2‐benzothiophen) butyric acid is reported and compared with that of 4. amino‐3‐(2‐thiényl) butyric acid. For both molecules, the __γ__‐aminobutyric acid (GAB) chains show almost identical conformations. C~12~H~13~NO~2~S, Mw = 235.0, P2'~1~/c, a = 17.8
The average of five replicate determinations for percent intact melphalan in a single vial of dosage formulation was 88.7% with a standard deviation of 1 (range = 2.5 %). Variations of less than 3 % were found in the assay of several vials from the same production lot. The samples and reference sol